William E. Steinkrauss

Net worth: 45 328 $ as of 31/03/2024

39 year

Health Technology

Consumer Services

Profile

William E.
Steinkrauss worked as a Director-Technical Accounting & Reporting at OvaScience, Inc. from 2015 to 2016.
Prior to that, he was a Senior Manager-Technical Accounting at Cubist Pharmaceuticals LLC from 2012 to 2015.
Currently, he is the Chief Financial & Administrative Officer at Curis, Inc. starting from 2016.
Steinkrauss completed his undergraduate and graduate degrees from Boston College.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
CURIS, INC. 0.07%	31/07/2023	4,170 ( 0.07% )	45 328 $	31/03/2024

Former positions of William E. Steinkrauss

Companies	Position	End
CURIS, INC.	Director of Finance/CFO	05/08/2022
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Corporate Officer/Principal	01/08/2016
CUBIST PHARMACEUTICALS INC	Corporate Officer/Principal	01/05/2015

See the detail of William E. Steinkrauss's experience

Training of William E. Steinkrauss

Boston College

Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of William E. Steinkrauss's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
CURIS, INC.	Health Technology

Private companies	2
Cubist Pharmaceuticals LLC Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA.	Health Technology
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Health Technology